Annovis Bio (ANVS) News Today $2.51 -0.22 (-8.06%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.54 +0.03 (+1.24%) As of 08/1/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Buy" by BrokeragesJuly 30 at 2:47 AM | americanbankingnews.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 30 at 2:45 AM | marketbeat.comAnnovis Bio Stock Short Interest Report | NYSE:ANVS - BenzingaJuly 23, 2025 | benzinga.comAnnovis Bio to Present Key Findings at Alzheimer’s Association International ConferenceJune 27, 2025 | msn.comAnnovis to Attend the AAIC 2025 with Four Poster PresentationsJune 26, 2025 | globenewswire.comAnnovis Bio rises 16.3%June 24, 2025 | msn.comWe Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth CarefullyJune 22, 2025 | finance.yahoo.comAnnovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing ComplianceJune 20, 2025 | finanznachrichten.deAnnovis Bio Secures NYSE Approval to Regain Compliance with Listing StandardsJune 20, 2025 | msn.comAnnovis Announces NYSE Acceptance of Plan to Regain Listing ComplianceJune 19, 2025 | globenewswire.comQ2 Earnings Estimate for Annovis Bio Issued By HC WainwrightJune 11, 2025 | marketbeat.comHC Wainwright Comments on Annovis Bio Q1 EarningsJune 10, 2025 | marketbeat.comAnnovis Bio: H.C. Wainwright senkt Kursziel auf 12 US-DollarJune 10, 2025 | de.investing.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of "Buy" from AnalystsJune 10, 2025 | marketbeat.comAnnovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC WainwrightJune 9, 2025 | marketbeat.comAnnovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program DevelopmentJune 6, 2025 | msn.comAnnovis to Host Webinar and Live Q&A on June 24, 2025June 5, 2025 | globenewswire.comAnnovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial ProgressMay 18, 2025 | msn.comCanaccord senkt Kursziel für Annovis Bio Aktie auf 17 US-Dollar; behält Kaufempfehlung beiMay 15, 2025 | de.investing.comAnnovis Bio Inc.: Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deAnnovis Provides Corporate Updates and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comAnnovis Bio hires new director of biostatistics amid AD trialMay 1, 2025 | uk.investing.comAnnovis Bio stellt neuen Direktor für BiostatistikApril 29, 2025 | de.investing.comAnnovis Bio Appoints Hui Liu as Director of BiostatisticsApril 29, 2025 | globenewswire.comAnnovis Bio-Aktie stürzt auf 52-Wochen-Tief von 1,14 US-DollarApril 10, 2025 | de.investing.comAnnovis Bio Receives Non-Compliance Notice from NYSEMarch 29, 2025 | msn.comAnnovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEMarch 29, 2025 | finanznachrichten.deAnnovis Bio receives noncompliance notification from NYSEMarch 28, 2025 | markets.businessinsider.comAnnovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025March 27, 2025 | msn.comAnnovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEMarch 27, 2025 | globenewswire.comAnnovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramMarch 25, 2025 | finance.yahoo.comAnnovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramMarch 25, 2025 | globenewswire.comAnnovis Bio Reports Progress in Clinical Trials and Improved Financial PositionMarch 24, 2025 | msn.comAnnovis Bio Inc.: Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 22, 2025 | finanznachrichten.deAnnovis Bio reports Q4 EPS (43c) vs. ($2.24) last yearMarch 22, 2025 | markets.businessinsider.comAnnovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 21, 2025 | globenewswire.comAnnovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development SummitMarch 13, 2025 | msn.comAnnovis Joins Experts at Drug Development Summit to Redefine Parkinson's TreatmentMarch 11, 2025 | globenewswire.comAnnovis Bio-Aktie fällt auf 52-Wochen-Tief von 2,42 US-DollarFebruary 20, 2025 | de.investing.comAnnovis Bio to Host Patient-Centered Webcast on Key Clinical DevelopmentsFebruary 20, 2025 | msn.comAnnovis to Host Patients' Live Forum on February 27, 2025February 19, 2025 | globenewswire.comAnnovis Bio-Aktie fällt auf 52-Wochen-Tief bei 2,59 US-DollarFebruary 11, 2025 | de.investing.comAnnovis Bio stock hits 52-week low at $2.59 amid sharp declineFebruary 11, 2025 | msn.comAnnovis Bio downgraded to Hold from Buy at D. Boral CapitalFebruary 11, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Annovis Bio (ANVS)February 11, 2025 | msn.comAnnovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 7, 2025 | globenewswire.comAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s DiseaseFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio announces first patients entered Phase 3 study of buntanetapFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug DevelopmentFebruary 6, 2025 | theglobeandmail.comAnnovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s ResearchFebruary 6, 2025 | msn.com Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼0.670.63▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼23▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALX Oncology News Today Rapt Therapeutics News Today MediWound News Today Tiziana Life Sciences News Today Eledon Pharmaceuticals News Today DiaMedica Therapeutics News Today Y-mAbs Therapeutics News Today Caribou Biosciences News Today 4D Molecular Therapeutics News Today Alumis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
